ABCL · AbCellera Biologics Inc.
$11.32
-0.25 (-2.16%)
At close · Aug 21
Market Cap
$3.47B
Shares
306.61M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$75.13M
+160.6%
FY2025
Net Income
-$146.41M
+10.1%
FY2025
Operating Margin
-288.98%
+802.7pp
FY2025
Diluted EPS
-$0.49
+10.9%
FY2025
Operating Cash Flow
-$131.3M
-20.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $66.17M | $75.13M | $28.83M | $38.03M | $485.42M | $375.2M | $233.16M | $11.61M | |
| $197.77M | $186.83M | $167.26M | $175.66M | $107.88M | $62.06M | $29.39M | $10.11M | |
| $11.9M | — | $12.78M | $14.18M | $11.27M | $6.91M | $3.84M | $1.26M | |
| — | $83.23M | $85.49M | $75.18M | $55.49M | $41.85M | $11.91M | $2.75M | |
| — | $3.7M | $14.3M | $11.6M | $10.5M | $10.1M | $2.5M | $0 | |
| — | — | — | $24.4M | $27.84M | $14.45M | $4.84M | $1.6M | |
| $291.33M | $292.23M | $343.6M | $275.23M | $268.91M | $170.79M | $77.12M | $15.73M | |
| -$225.15M | -$217.1M | -$314.77M | -$237.21M | $216.51M | $204.41M | $156.03M | -$4.12M | |
| — | -288.98% | -1091.69% | -623.82% | 44.6% | 54.48% | 66.92% | -35.45% | |
| — | — | — | -$212.81M | $244.35M | $218.86M | $160.87M | -$2.51M | |
| $26.45M | $28.33M | $38.47M | $42.25M | $16.08M | $3.33M | $293K | $155K | |
| $28.39M | $39.51M | $114.37M | $63.18M | $22.59M | $14.74M | $1.8M | $1.91M | |
| — | — | $1.7M | $1.8M | $900K | $0 | — | — | |
| -$196.77M | -$177.6M | -$200.4M | -$174.03M | $239.1M | $219.15M | $157.83M | -$2.21M | |
| -$32.11M | -$31.18M | -$37.54M | -$27.63M | $80.58M | $65.69M | $38.92M | — | |
| -$164.66M | -$146.41M | -$162.86M | -$146.4M | $158.52M | $153.46M | $118.92M | -$2.21M | |
| — | -194.88% | -564.83% | -385% | 32.66% | 40.9% | 51% | -19.04% | |
| -$164.66M | -$146.41M | -$162.86M | -$146.4M | $158.52M | $153.46M | $85.1M | -$2.21M | |
| -$165.15M | -$146.27M | -$165.52M | -$146.73M | $156.85M | $153.74M | $118.92M | -$2.21M | |
| USD/shares | — | -$0.49 | -$0.55 | -$0.51 | $0.56 | $0.56 | $0.53 | -$0.01 |
| USD/shares | — | -$0.49 | -$0.55 | -$0.51 | $0.50 | $0.48 | $0.45 | -$0.01 |
| shares | — | 298.71M | 294.33M | 289.17M | 285.06M | 275.76M | 159.2M | 151.33M |
| shares | — | 298.71M | 294.33M | 289.17M | 314.83M | 318.29M | 263.13M | 151.33M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.33×
EV/EBIT
—
Peer median 23.88×
P/E (TTM)
—
Peer median 18.05×
Peer medians compare against the 229 similar-size Biotechnology companies (of 545 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Canada | $64,000,000 | $26,200,000 | $36,000,000 | $484,200,000 | $353,400,000 |
| United States | $11,100,000 | $2,700,000 | $2,000,000 | $1,200,000 | $21,800,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| License | $46,920,000 | $1,049,000 | $969,000 | $696,000 | $20,778,000 | — | — |
| Research Fees | $27,208,000 | $26,284,000 | $35,556,000 | $40,802,000 | $19,076,000 | $19,848,000 | $11,612,000 |
| Milestone Payments | $1,000,000 | $1,500,000 | $1,500,000 | $900,000 | $8,000,000 | $15,000,000 | — |
| Royalty | — | — | — | $443,026,000 | $327,349,000 | $198,307,000 | — |
Key facts
CIK
1703057
CUSIP
00288U106
13F (30d)
131 filings
131 filers
Visit website
Investor relations